GlassScriptPhysician profile
Jayanta Chaudhuri
NPI 1497716492
$3,770.90
in general payments reported to CMS, 2019-2025
27 companies · $231 in 2025
The $231 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $586 · 2020: $1,398 · 2021: $720 · 2022: $328 · 2023: $243 · 2024: $265 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $739.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $695.53 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $672.37 | 2019-2024 | Mounjaro |
| Esperion Therapeutics, INC. | $653.99 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $324.28 | 2020-2023 | |
| Novo Nordisk INC | $183.80 | 2019-2025 | |
| Beta Bionics, INC. | $135.21 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Astrazeneca Pharmaceuticals LP | $108.31 | 2020-2024 | Airsupra |
| Amgen INC. | $79.84 | 2019-2024 | Tepezza |
| Amarin Pharma, INC. | $78.84 | 2019-2021 | |
| Abbott Laboratories | $78.82 | 2020-2023 | Freestyle Libre 3 |
| Pfizer INC. | $78.62 | 2019-2024 | |
| Glaxosmithkline, LLC. | $75.48 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $75.18 | 2020-2023 | |
| Dexcom, INC. | $74.35 | 2021-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $71.65 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $64.14 | 2023-2024 | Minimed 780g |
| Insulet Corporation | $54.19 | 2021-2023 | Omnipod |
| Ascendis Pharma Endocrinology INC | $44.31 | 2025 | Yorvipath |
| Amneal Pharmaceuticals LLC | $36.59 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.67 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $27.27 | 2019-2021 | |
| Medtronic Minimed, INC. | $24.90 | 2020 | |
| Mannkind Corporation | $22.40 | 2021 | |
| Recordati_rare_diseases_inc. | $20.06 | 2022 | |
| Eusa Pharma (US) LLC | $20.06 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.35 | 2021 | |
| Corcept Therapeutics | $18.69 | 2024 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayanta Chaudhuri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.